Transthyretin Amyloidosis Treatment Market Deep Research Report with Forecast to 2034

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Transthyretin Amyloidosis Treatment Market - (By Type (ATTR-PN, ATTR-CM), By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

According to the latest research by InsightAce Analytic, the Transthyretin Amyloidosis Treatment Market Size is valued at USD 5.5 Bn in 2024 and is predicted to reach USD 11.7 Bn by the year 2034 at a 8.0% CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2890

Transthyretin amyloidosis (ATTR amyloidosis) treatment comprises a range of medical interventions aimed at managing disease progression and mitigating the impact of this rare, progressive, and potentially life-threatening condition. The disorder is caused by the accumulation of misfolded transthyretin proteins in various organs and tissues. Current treatment strategies include pharmacological therapies that stabilize transthyretin or suppress its production, complemented by supportive care measures to address symptoms and prevent associated complications.

Increasing awareness of rare diseases, together with advancements in diagnostic technologies, is expected to improve the identification of ATTR amyloidosis, leading to a higher diagnosed patient population and supporting market expansion. In parallel, the growing number of clinical research programs focused on the development of innovative pipeline therapies for transthyretin amyloidosis and related disorders is further strengthening the market outlook.

List of Prominent Players in the Transthyretin Amyloidosis Treatment Market:
• Acrotech Biopharma, LLC
• Alnylam Pharmaceuticals, Inc.
• AstraZeneca PLC
• Astellas Pharma Inc.
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Prothena Biosciences Limited
• Pfizer Inc.
• SOM Innovation Biotech, S.L.
• Abbvie, Inc.
• Sanofi
• Eidos Therapeutics, Inc
• BELLUS Health Inc

Market Dynamics:
Drivers-
The rising prevalence of transthyretin amyloidosis, particularly among the aging population, is a significant factor driving market growth. With the global elderly population projected to reach 1.5 billion, the incidence of ATTR amyloidosis is expected to rise accordingly. According to a report by Prothena, over 400,000 individuals globally are affected by wild-type ATTR amyloidosis (ATTRwt), while approximately 50,000 individuals suffer from hereditary ATTR amyloidosis (hATTR). Research from NCBI highlights that aging is a major risk factor for ATTRwt, with the heart being the primary organ affected. To enhance awareness and early diagnosis, various organizations have launched initiatives aimed at educating healthcare professionals and patients.

Curious About This Latest Version Of The Report? Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/2890

Challenges:
A key challenge in the transthyretin amyloidosis treatment market is the limited awareness among healthcare professionals, leading to misdiagnosis and improper treatment. Additionally, the high cost of newly approved medications presents a financial barrier to patient accessibility. For example, a study by Alnylam Pharmaceuticals, Inc. indicates that the annual cost of Patisiran and Inotersen treatments is approximately $450,000 USD, posing affordability concerns for patients and healthcare systems.

Regional Trends:
The North American market is anticipated to hold a dominant share in revenue due to increased diagnosis rates, growing treatment adoption, and expanding prescription volumes. A significant milestone in the region was Health Canada's approval of ONPATTRO, a treatment for hATTR polyneuropathy, which has contributed to greater access to innovative therapies.

Additionally, the Middle East and Africa are witnessing substantial market growth, driven by high unmet medical needs, rising approval rates for novel therapies, and increasing disease prevalence.

Unlock Your GTM Strategy:
https://www.insightaceanalytic.com/customisation/2890

Segmentation of Transthyretin Amyloidosis Treatment Market-
By Type-
• ATTR-PN
• ATTR-CM
By Therapy-
• Targeted Therapy
o Onpattro
o Inotersen
o Vyndaqel/Vyndamax
• Supportive Therapy
• Pipeline Therapy
By Disease Type-
• Hereditary Transthyretin Amyloidosis
o Polyneuropathy
o Cardiomyopathy
o Mixed Type
• Wild Type Amyloidosis
By Distribution Channel-
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Get more information:
https://www.insightaceanalytic.com/report/transthyretin-amyloidosis-treatment-market/2890

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.

Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Official Site Visit: www.insightaceanalytic.com
Tel.: +1 607 400-7072
Email: info@insightaceanalytic.com
Follow US On :
LinkedIn @ https://www.linkedin.com/company/insightace-analytic-pvt-ltd/
Twitter @ https://x.com/MInsightace
YouTube @ https://www.youtube.com/@InsightAceAnalytic
Instagram @https://www.instagram.com/insight_ace_analytic/

This release was published on openPR.